Yokogawa to Supply Energy Management System for Yuri Green Hydrogen Project in Australia
5.9.2023 03:00:00 EEST | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO: 6841) announces that its subsidiary Yokogawa Australia has received an order from Monford Group Pty Ltd. to supply an energy management system (EMS) for the initial phase (“phase 0”) of the Yuri Green Hydrogen Project (hereafter, Yuri), which is constructing an industrial-scale renewable hydrogen production complex in Australia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904401589/en/
Conceptual drawing showing the Yuri project facilities at the completion of phase 0. The existing YPF ammonia plant is in the foreground and the solar plant is in the background. (Source: ENGIE S.A.)
The Yuri project is being undertaken in the Pilbara region of Western Australia by Yuri Operations Pty Ltd, a joint venture between ENGIE Renewables Australia Pty Ltd and Mitsui & Co., Ltd. A consortium consisting of the engineering, procurement, construction and commissioning (EPCC) companies Technip Energies and Monford Group Pty Ltd. is constructing these facilities, which will consist of an 18-megawatt solar power plant, an 8-megawatt battery energy storage system (BESS), and a 10-megawatt electrolyzer. Using carbon-free solar energy, this facility will be able to produce up to 640 tons of green hydrogen per year. The hydrogen will be used as a feedstock to produce green ammonia at an adjacent ammonia plant operated by Yara Pilbara Fertiliser Pty Ltd (YPF). YPF is a wholly owned subsidiary of Yara International ASA, which is one of the world's largest producers of nitrogen-based mineral fertilizers.
For the control of the solar power plant, BESS, and electrolyzer, Yokogawa Australia will supply an EMS that is developed by Yokogawa Group company PXiSE Energy Solutions LLC. This EMS will be combined with an integrated control system (ICS) centering on the Collaborative Information Server solution that Yokogawa will also be providing for phase 0 of this project, under a separate contract*1. Once these systems are installed and integrated, the Yuri facility’s renewable energy production will be autonomously managed to ensure consistent stability and power quality based on the operating requirements of the adjacent ammonia plant, the weather, and other factors.
PXiSE’s grid control solutions have already been highly evaluated at a Horizon Power project in Western Australia*2. Horizon Power serves the largest power supply area in the world, and following a successful rollout in Onslow, the solutions will be adopted in 34 additional Horizon Power microgrids. Also, the ability of Yokogawa Australia's Technical Excellence Center in Perth, Western Australia, to provide technical support and engineering services backed by many years of experience in providing cutting-edge solutions to a wide range of industries in Australia was also evaluated.
Commenting on Yokogawa’s participation in this project, Koji Nakaoka, a Yokogawa senior vice president and head of the company's Energy & Sustainability Business Headquarters and Global Sales Headquarters, said, “In a world in which systems are becoming closely integrated, based on the system of systems (SoS) concept, we will contribute to our customer’s ESG management by offering high value-added solutions, including the integration of plant control and energy management systems to enable the timely control of complex power systems.”
*1 Yokogawa to Provide Integrated Control System for Australian Green Hydrogen Project - First-ever use in Australia of green hydrogen as feedstock for ammonia production – https://www.yokogawa.com/news/press-releases/2022/2022-11-30-01/
*2 Horizon Power and PXiSE Energy Solutions Successfully Operate World’s First 100% Solar-Plus-Storage-Only Community Grid https://pxise.com/horizon-power-and-pxise-energy-solutions-successfully-operate-worlds-first-100-solar-plus-storage-only-community-grid/
PXiSE DERMS used in 34 Horizon Power microgrids https://pxise.com/pxise-derms-used-in-34-horizon-power-microgrids/
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,000+ employees in a global network of 129 companies spanning 60 countries.
For more information, visit www.yokogawa.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904401589/en/
Contact information
PR Section
Integrated Communications Center
Yokogawa Electric Corporation
Yokogawa-pr@cs.jp.yokogawa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom